Trinity Biotech plc
19.80%
85,800,000
888721
896438504
Mar 20, 2025
Mar 25, 2025, 06:29 PM
Reporting Persons (5)
This is a joint filing. The reported shares may overlap between reporting persons and should not be summed.
| Name | Type | % of Class | Aggregate | Sole Voting | Shared Voting |
|---|---|---|---|---|---|
| Perceptive Advisors LLC | Other | 19.80% | 85,800,000 | 0 | 85,800,000 |
| Perceptive Credit Advisors LLC | Other | 19.80% | 85,800,000 | 0 | 85,800,000 |
| Joseph Edelman | Individual | 19.80% | 85,800,000 | 0 | 85,800,000 |
| Perceptive Credit Holdings II, L.P. | Partnership | 10.60% | 45,800,000 | 0 | 45,800,000 |
| Perceptive Credit Holdings III, L.P. | Partnership | 9.20% | 40,000,000 | 0 | 40,000,000 |
Disclosure Items (2)
Class A Ordinary Shares, $0.0109 par value per share
Trinity Biotech plc
IDA Business Park, Co. Wicklow, L2, A98 H5C8
Items 5(a)-(b) of the Schedule 13D is amended and supplemented as follows: The information set forth in rows 11 and 13 of the cover pages to this Amendment No. 4 to the Schedule 13D is incorporated by reference. The percentage set forth in row 13 is based on 383,881,600 Ordinary Shares outstanding as of March 15, 2025, as reported in the Issuer's registration statement on Form F-3 filed with the Securities and Exchange Commission on March 21, 2025, and, with respect to Credit Fund II, assumes the exercise of 500,000 Warrants held by Credit Fund II into 500,000 ADSs representing 10,000,000 Ordinary Shares, and with respect to Credit Fund III, assumes the exercise of 2,000,000 Warrants held by Credit Fund III into 2,000,000 ADSs representing 40,000,000 Ordinary Shares. The Warrants may not be exercised if the Reporting Persons would beneficially own more than 9.99% of the Issuer's outstanding Ordinary Shares after giving effect to such exercise.
The information set forth in rows 7 through 10 of the cover pages to this Amendment No. 4 to the Schedule 13D is incorporated by reference.